Question explored with the scientific record
Is ivermectin an effective treatment for cancer?
The short version: ivermectin shows real anticancer activity in dozens of preclinical studies, but no human trial has tested it as a cancer treatment.
Every study in the evidence is preclinical—petri dishes and mice [1, 2, 4, 5, 6, 7, 10, 11]. The mechanisms are plausible and multiple: ivermectin blocks WNT signaling [1, 6], triggers immunogenic cell death through ATP-purinergic receptors [7, 10], induces autophagy via AKT/mTOR inhibition [11], and converts "cold" tumors to "hot" ones that respond to checkpoint inhibitors [5]. In mouse models of breast cancer, glioma, and hepatocellular carcinoma, ivermectin shrinks tumors and improves survival [2, 4, 10]. A 2026 study using platelet-membrane-coated ivermectin nanocrystals achieved 98.9% tumor inhibition in a liver cancer model [10].
But the gap between a mouse and a human is enormous. None of these studies were funded by a manufacturer—they are academic, which is a point in their favor. The problem is that no human cancer trial exists. The evidence base is entirely in vitro and in vivo animal work. Ivermectin is a cheap, off-patent drug, so no company will pay for the expensive phase II/III trials needed to prove it works in people. That is a structural barrier, not a scientific refutation.
| Cancer type | Model | Best reported effect | Source |
|---|---|---|---|
| Triple-negative breast | Mouse xenograft | 1.8-fold tumor reduction vs uncoated drug | [4] |
| Hepatocellular carcinoma | Mouse orthotopic | 98.9% tumor inhibition with nanoformulation | [10] |
| Glioma | Rat orthotopic | 70% tumor volume reduction (intranasal) | [2] |
| Canine mammary | Mouse xenograft | Reduced tumor volume, no toxicity | [1] |
My call: ivermectin is a promising anticancer agent in preclinical models, but there is zero human evidence. A patient should not substitute it for standard care. Confidence: low for human efficacy, moderate for preclinical plausibility.
Sources examined 12
-
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The study shows that repurposed anthelmintic ivermectin inhibits canine mammary tumor growth by causing G1 cell cycle arrest via downregulation of cyclin D1 and CDK4 and by suppressing WNT/β-catenin signaling, with efficacy observed in vitro in canine mammary tumor cell lines an…
DOI: 10.1186/s12917-019-2026-2 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates
This study synthesizes ten ivermectin bioconjugates with diverse bioactive partners (cinchona alkaloids, nucleosides, metronidazole, betulinic acid, artesunate) using carbonate, urethane, or click-type linkers, and evaluates their antiproliferative activity against four human ca…
DOI: 10.1021/acsomega.5c02998 -
Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management
The study develops biomimetic platelet-membrane camouflaged ivermectin nanocrystals (PMV/Ivm-NC) using a sonoprecipitation method and platelet membrane coating to achieve targeted tumor homing, immunogenic cancer cell death, and enhanced antitumor/antimetastatic effects against …
DOI: 10.1007/s13346-025-02032-2 -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
This study demonstrates that ivermectin can convert cold breast tumors into hot tumors by inducing immunogenic cell death and enhancing T cell infiltration, thereby synergizing with immune checkpoint blockade for improved treatment outcomes.
DOI: 10.1038/s41523-021-00229-5 -
The river blindness drug I vermectin and related macrocyclic lactones inhibit WNT ‐ TCF pathway responses in human cancer
This study identifies Ivermectin and related macrocyclic lactones as effective inhibitors of the WNT-TCF signaling pathway in human cancer cells, suggesting their potential therapeutic use against various cancers.
DOI: 10.15252/emmm.201404084 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer
Single-cell RNA sequencing of colorectal cancer reveals neutrophil differentiation–related genes that predict immunotherapy response and identifies Ivermectin as a potential adjunct therapeutic strategy.
DOI: 10.1186/s12885-025-15355-7 -
Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway
A phenotype-based zebrafish screen identified Wnt/b-catenin pathway inhibitors with low developmental toxicity, uncovering roles for GGTase, Rac, and JNK in pathway control, and demonstrating anti-tumor activity and potential for drug repositioning in mouse models.
DOI: 10.1248/yakushi.16-00229-2 -
Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma
A novel ivermectin–MnO2 nanoimmunoamplifier (IMN) was designed to potentiate chemoimmunotherapy for hepatocellular carcinoma by sustaining eATP signaling through P2X4R/P2X7R, alleviating tumor hypoxia, reducing eATP degradation via CD39/CD73, and robustly activating the NLRP3 in…
DOI: 10.34133/bmr.0278 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors
In mice, potent P-glycoprotein inhibitors SDZ PSC 833 and SDZ 280-446, but not cyclosporin A, reduced tolerance to cyclosporin A and ivermectin, causing CNS toxicity consistent with blood-brain barrier Pgp blockade.
DOI: 10.1002/ijc.2910630220